COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- New high-speed rail route to further fuel China's winter sports boom
- China ready to work with countries to deepen engineering exchanges and collaboration
- Central delegation continues to visit officials, residents in multiple areas of Xinjiang
- Nineteen provinces invest billions toward Xinjiang’s education development since 2012
- China launches 11th batch of internet satellites to boost global network
- Authorities warn of COVID-19 rebound and rise in other respiratory diseases
